Benefits
Anxiety with mild stimulating profile (Russian indication)
Russian approval for anxiety states. Unique mechanism: GABA prodrug providing anxiolysis without typical sedation due to niacin moiety's vasodilatory/stimulating effects. Mechanism: in CNS, cleaved to release GABA (anxiolytic) + niacin (vasodilator/possibly mild stimulant). Distinct from benzodiazepines (sedating) and from selank (peptide). Read this as a foreign regulator's indication rather than a demonstrated effect. No controlled human trial of picamilon for anxiety has been published, and no study cited on this page measured an anxiety rating scale in a single person. The closest human data are Russian open-label studies in chronic cerebral ischemia patients that scored autonomic dysfunction and sleep quality, not anxiety. The anxiolytic-without-sedation description above is mechanistic reasoning plus rodent work, and rodent work that specifically found the effect was not mediated by benzodiazepine receptors.
Cerebrovascular disease and cerebral circulation
Russian indication for cerebrovascular insufficiency and chronic cerebral ischemia. Mechanism: niacin component provides vasodilation enhancing cerebral blood flow. Chronic cerebral ischemia and cerebrovascular insufficiency are diagnosed diseases, so this is the indication of a foreign prescription medicine and not something anyone should buy a supplement to treat. The supporting studies are real but weak. A 2024 study in 50 patients with stage II chronic cerebral ischemia opened with 10 days of picamilon given intravenously at 200 mg before switching to 50 mg tablets three times a day for 60 days. A companion 2024 study in 44 patients with stage I disease compared an oral-only regimen against an intramuscular-then-oral one. Neither had a placebo or untreated group, both came from the same Moscow investigators, and part of the dosing in most arms was by injection, which is not how anyone takes a supplement.
Depression: a Russian drug indication, and the human comparison was null
Depression is a diagnosed illness, so this is an indication approved for a prescription medicine in Russia and not a reason to take a supplement. It is also the one outcome where picamilon has been measured against a comparator and did not win. An open randomized study in 278 patients with chronic cerebral ischemia gave one group a picamilon plus ginkgo combination and the other ginkgo alone for 90 days. Cognitive scores favoured the combination, but the two groups showed no significant difference on the Hamilton Depression Rating Scale. Those patients were selected for cerebral ischemia rather than for depression, so this is not a depression trial, but it is the largest picamilon study available and adding picamilon produced no measurable mood advantage in it.
GABA prodrug delivery (mechanism advantage)
Distinguishing pharmacological feature: Picamilon is GABA prodrug. Pure GABA cannot cross BBB efficiently. Niacin component provides lipophilicity for BBB penetration; once in CNS, amide bond cleaved by amidases to release GABA + nicotinic acid. The design rationale resembles phenibut (phenyl-GABA), but the delivery step has never been demonstrated in a person. An FDA laboratory screen published in 2023 tested picamilon against 50 safety-related receptors, ion channels, enzymes and transporters and found weak or no binding to any of them. That result is consistent with the parent molecule being inert until it is cleaved, which is what a prodrug should look like, but it also means picamilon has no demonstrated direct activity of its own, and the same authors noted how little in silico, in vitro and in vivo data exists on this compound.
Migraine prevention: a drug use with no human trial behind it
Migraine is a diagnosed neurological disorder, so preventing it is a drug use rather than a supplement benefit. No human study of picamilon for migraine, of any design, is indexed in PubMed. The one migraine-related experiment on record is a 1989 rat brain synaptosome study of antimigraine drugs in which methysergide, nicergoline and tolfenamic acid all disturbed serotonin transport while picamilon failed to affect either serotonin uptake or release. Nothing available supports taking picamilon for headaches.
Mechanism of action
GABA prodrug — CNS amidase cleavage
Picamilon is N-nicotinoyl-GABA — synthetic conjugate cleaved in CNS by amidase enzymes to release: (1) GABA — inhibitory neurotransmitter providing anxiolytic effects via GABA-A receptor activation; (2) nicotinic acid (niacin) — vasodilator with vitamin B3 activity. Dual delivery mechanism distinguishes from pure GABA-mimetic compounds.
Niacin vasodilation enhancing cerebral blood flow
Niacin component provides vasodilation — enhances cerebral blood flow and microcirculation. This is the stated basis for the cerebrovascular indications, and it is worth keeping the quantity in view. At the usual 150 mg a day of picamilon, complete cleavage would liberate only about 80 to 90 mg of nicotinic acid a day. That is enough to explain skin flushing, which starts at a few tens of milligrams, but it is far below the 1 to 2 grams a day used in the niacin lipid trials, and even those gram-level doses failed to reduce cardiovascular events when added to statin therapy. The niacin fragment is not a reason to expect heart or cholesterol benefits.
GABA-A receptor activation (post-cleavage)
This step is assumed rather than shown, and the animal pharmacology is messier than the assumption. In the rat study most often cited for it, picamilon's effect on cerebral blood flow was not blocked at all by bicuculline, a competitive GABA-A antagonist, and was only reduced by picrotoxin, which blocks the receptor's chloride channel. A separate rat experiment reported that the anxiolytic activity of nicotinoyl-GABA was not mediated through benzodiazepine receptors. No human study has measured GABA-A engagement after a swallowed dose of picamilon.
Modest BBB penetration via lipophilic conjugate
Amide-bonded niacin-GABA conjugate is more lipophilic than free GABA — crosses BBB. Once in CNS, cleaved to active components. Mechanism design similar to other prodrug strategies.
Clinical trials
Open cohort clinical study with no control group and no placebo, conducted at Sechenov First Moscow State Medical University and published in 2024. Picamilon was given first as 200 mg intravenously for 10 days, then as 50 mg tablets three times a day for 60 days, 70 days of treatment in total. Because the course opens with 10 days of injection, the result cannot be read as the effect of an oral product. Assessments were the MoCA cognitive scale, the Vane autonomic scale, the Fedin neurological scale, the Levin sleep scale, Doppler ultrasound of cranial vessels, and methylated arginine markers of endothelial function.
50 patients aged 51 to 69, average age 62, all with a diagnosis of stage II chronic cerebral ischemia. No healthy participants, and no comparison group of any kind.
MoCA cognitive scores rose from 20.9 at baseline to 24.6 after the course and 25.9 six weeks later. Sleep normalized in 55 percent of patients by the second visit and 81 percent by the third. Neurological scores on the Fedin scale fell from 17.4 to 8.06 and then to 5.31. Autonomic status normalized in 38 percent. Tolerability was rated good in 98 percent. The authors also report faster cerebral blood flow, a thinner intima-media complex and lower ADMA. Every one of those numbers should be read against the design: there was no control group and no blinding, so patients and raters both knew what was being given, and each of these scales is open to expectancy. The intima-media result deserves particular caution, since that marker does not normally change measurably over ten weeks. The participants were neurology patients taking a prescription drug, the first ten days of it by injection.
Animal pharmacology experiment in rats, published in Russian in 2005. It is not a clinical study of any kind. Cerebral blood flow responses to picamilon and to afobazole were measured with and without the GABA receptor blockers bicuculline and picrotoxin.
Rats. No human participants.
Picamilon's effect on cerebral blood flow in rats was not affected by bicuculline, a competitive GABA-A antagonist, but was significantly reduced by picrotoxin, which blocks the chloride channel of the GABA receptor. The authors read that as partial involvement of the GABA system. It is a rodent result about blood flow only. It measured nothing about anxiety, mood or cognition, it confirms nothing about prodrug delivery in humans, and it does not transfer to a person swallowing a capsule.
FDA Warning Letters issued to multiple supplement companies marketing picamilon.
Supplement companies marketing picamilon as dietary supplement in US.
FDA determined picamilon not a legal dietary ingredient — declared synthetic drug rather than natural compound (vitamin, herb, or other DSHEA-eligible substance). Many companies removed picamilon products following warning letters. This is a settled determination, not an open question. Picamilon is not eligible for sale in a US dietary supplement, whatever a vendor's label says. What ends up in the bottle is unreliable as well. When researchers bought 31 supplements labelled as containing picamilon and measured them, 30 contained it at anywhere from 2.7 to 721.5 mg per recommended daily serving, a spread of more than 250-fold, with the top of that range several times the 150 mg a day used in Russian medical practice. A later analysis of memory and focus products found picamilon at up to 90 mg a serving, one of several unapproved drugs turning up in products whose labels did not list everything they contained.